Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial Evaluating the Safety and Preliminary Efficacy of CD44/CD133 Dual-Target Tris-CAR-T Cell Therapy in Patients With Newly Diagnosed Glioblastoma

NCT07873996 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT07873996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07873996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial Evaluating the Safety and Preliminary Efficacy of CD44/CD133 Dual-Target Tris-CAR-T Cell Therapy in Patients With Newly Diagnosed Glioblastoma
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
October 15, 2030
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed glioblastoma, idh-wildtype